IMPACT Therapeutics, Inc. (IMPACT Therapeutics) has issued a circular convening an extraordinary general meeting (EGM) for 10:00 a.m. on 27 July 2026 in Shanghai to seek shareholder approval on two special resolutions.
1. Share Award Scheme • Scope and term: The proposed 2026 Share Award (Existing Shares) Scheme will run for up to ten years from its adoption date. • Mandate limit: Awards will be satisfied solely with existing H shares purchased by an independent trustee and are capped at 5.00% of the Company’s issued share capital (excluding any treasury shares) on the adoption date. • Eligibility: Senior management and other employees of the Company and its subsidiaries, excluding jurisdictions where grants are legally restricted. • Vesting mechanics: The Board may set performance, service or claw-back conditions; unvested awards lapse if participants leave under disqualifying circumstances. • Funding: Contributed from internal resources; the trustee will acquire shares on- or off-market at prevailing prices. No new shares will be issued, and the scheme is classified as an existing-share plan under HKEX Chapter 17. • Governance: Grants to directors, chief executives or substantial shareholders (or their associates) require prior approval from independent non-executive directors and must comply with connected-transaction rules.
2. Amendments to Articles of Association To align the registered capital and share capital table with the full exercise of the over-allotment option completed after the Company’s May 2026 Hong Kong IPO: • Registered capital will rise from RMB 276.17 million to RMB 282.46 million. • Total issued shares will increase from 276.17 million to 282.46 million H shares.
Shareholder Logistics • Register closure: 22–27 July 2026 (both days inclusive); only shareholders on record as of 27 July 2026 may vote. • Proxy forms must reach Computershare Hong Kong Investor Services by 10:00 a.m. on 26 July 2026.
Board View The Board recommends shareholders vote in favour of both proposals, citing the scheme’s role in aligning employee and shareholder interests and the necessity to update corporate documents following the IPO’s over-allotment option exercise.